NEW YORK, July 11, 2019 /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating claims on behalf of investors who purchased shares of Omnicell, Inc. ("Omnicell" or the "Company") (Nasdaq: OMCL).
Omnicell, Inc. provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide.
On July 11, 2019, Investor's Business Daily reported that GlassHouse Research "accused the medical stock of 'accounting gimmicks,' including prematurely recording revenue." "Significant declines in revenue and earnings await Omnicell as the company has obfuscated its financials by prematurely recognizing revenue in prior periods and failing to write-off legacy inventory," GlassHouse reportedly stated in its report initiating coverage of Omnicell stock.
On July 11, 2019, shares of Omnicell declined over 12% on heavier than usual volume.
If you purchased Omnicell shares, and would like to discuss our investigation, please contact us by emailing jcampisi@kaplanfox.com or by calling 800-290-1952.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Kaplan Fox & Kilsheimer LLP, with offices in New York, San Francisco, Los Angeles, Chicago and New Jersey, has many years of experience in prosecuting investor class actions. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com. If you have any questions about your rights or interests, please contact:
Jeffrey P. Campisi
KAPLAN FOX & KILSHEIMER LLP
850 Third Avenue, 14th Floor
New York, New York 10022
(800) 290-1952
(212) 687-1980
Fax: (212) 687-7714
E-mail: jcampisi@kaplanfox.com
Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
350 Sansome Street, Suite 400
San Francisco, California 94104
(415) 772-4700
Fax: (415) 772-4707
E-mail: lking@kaplanfox.com
View original content:http://www.prnewswire.com/news-releases/investor-alert-kaplan-fox-investigates-omnicell-inc-nasdaq-omcl-300883643.html
SOURCE Kaplan Fox & Kilsheimer LLP